Companies › Philogen
8 active drug programs in 21 registered trials: 12 Phase 2, 6 Phase 1, 3 Phase 3; Oncology, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Daromun TNF-alpha-based immunotherapy | – | Phase 3 | Melanoma Stage IIIB | Dec 2027 |
| L19IL2 Fibronectin binding agent | FN1 | Phase 3 | Malignant Melanoma; Melanoma Stage III; Locally Advanced Basal Cell Carcinoma; Locally Advanced Cutaneous Squamous Cell Carcinoma … | May 2028 |
| L19TNF L19-targeting TNF fusion protein | TNF | Phase 3 | Malignant Melanoma; Glioblastoma; Melanoma Stage III; Locally Advanced Basal Cell Carcinoma … | Jul 2028 |
| Onfekafusp alfa | – | Phase 2 | Soft Tissue Sarcoma; Glioblastoma | Dec 2026 |
| IL12-L19L19 Antibody-cytokine fusion protein; IL-12 fused to L19 antibody targeting fibronectin | IL12A, IL12B, FN1 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| [177Lu]Lu-OncoFAP-23 Radioligand targeting fibroblast activation protein (FAP) | FAP | Phase 1 | FAP | May 2028 |
| F8IL10 Engineered human interleukin-10 fused to F8 antibody fragment targeting fibronectin | IL10 | Phase 1 | Rheumatoid Arthritis (RA) | Sep 2028 |
| [68Ga]Ga-OncoACP3 Gallium-68 labelled prostate cancer imaging agent | – | Phase 1 | Prostate Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04733183 | Onfekafusp alfa | Phase 2 | Soft Tissue Sarcoma | Oncology | Dec 2025 |
| NCT06336291 | L19TNF | Phase 2 | Glioblastoma | Oncology | Jun 2026 |
| NCT07600554 | [68Ga]Ga-OncoACP3 | Phase 1 | Prostate Cancer | Oncology | Oct 2026 |
| NCT04443010 | Onfekafusp alfa | Phase 1 | Glioblastoma | Oncology | Dec 2026 |
| NCT04471987 | IL12-L19L19 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT03567889 | Daromun | Phase 3 | Melanoma Stage IIIB | Oncology | Dec 2027 |
| NCT06640413 | L19IL2 | Phase 1 | FAP | Oncology | May 2028 |
| NCT06640413 | [177Lu]Lu-OncoFAP-23 | Phase 1 | FAP | Oncology | May 2028 |
| NCT06284590 | L19IL2 | Phase 2 | Melanoma Stage III | Oncology | Jul 2028 |
| NCT06284590 | L19IL2 | Phase 2 | Melanoma Stage III | Oncology | Jul 2028 |
| NCT06284590 | L19TNF | Phase 2 | Melanoma Stage III | Oncology | Jul 2028 |
| NCT07245992 | F8IL10 | Phase 1 | Rheumatoid Arthritis (RA) | Immunology | Sep 2028 |
| NCT02938299 | L19IL2 | Phase 3 | Malignant Melanoma | Oncology | Dec 2028 |
| NCT02938299 | L19TNF | Phase 3 | Malignant Melanoma | Oncology | Dec 2028 |
| NCT07227870 | L19IL2 | Phase 2 | Locally Advanced Basal Cell Carcinoma | Oncology | Feb 2031 |
| NCT07227350 | L19IL2 | Phase 2 | Locally Advanced Basal Cell Carcinoma | Oncology | Feb 2031 |
| NCT07227350 | L19IL2 | Phase 2 | Locally Advanced Basal Cell Carcinoma | Oncology | Feb 2031 |
| NCT07228442 | L19IL2 | Phase 2 | Locally Advanced Cutaneous Squamous Cell Carcinoma | Oncology | Feb 2031 |
| NCT07227870 | L19TNF | Phase 2 | Locally Advanced Basal Cell Carcinoma | Oncology | Feb 2031 |
| NCT07228442 | L19TNF | Phase 2 | Locally Advanced Cutaneous Squamous Cell Carcinoma | Oncology | Feb 2031 |
| NCT07227350 | L19TNF | Phase 2 | Locally Advanced Basal Cell Carcinoma | Oncology | Feb 2031 |
Johnson & Johnson (Janssen) Chengdu New Radiomedicine Technology Avacta Life Sciences Blue Earth Diagnostics Chia Tai Tianqing Pharmaceutical Group Prestige Biopharma Kahr Medical Taizhou Mabtech Pharmaceutical Chiesi Farmaceutici Teva Branded Pharmaceutical Products R&D
Lantheus Medical Imaging Chengdu New Radiomedicine Technology Stemline Therapeutics Minghui Pharmaceutical (Hangzhou) Pierre Fabre Medicament
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.